Here's what we'll cover
Here's what we'll cover
If you've lost meaningful weight on a GLP-1 medication, you've probably wondered: what happens when I stop? The honest answer has always been sobering. Most people regain a significant portion of their weight once GLP-1 treatment ends. Now, new research from Dartmouth-Hitchcock Medical Center is exploring whether a minimally invasive stomach procedure could help change that outcome.
The Weight Regain Problem With GLP-1 Medications
GLP-1 receptor agonists like Ozempic (semaglutide) and Mounjaro (tirzepatide) work partly by slowing digestion and reducing appetite through hormonal signaling in the brain. When you stop taking them, those signals fade.
Clinical trial follow-up data published in the journal Diabetes, Obesity and Metabolism found that participants who stopped Wegovy (semaglutide 2.4 mg) regained an average of two-thirds of their lost weight within one year. The body's hunger hormones rebound, metabolism adjusts, and the biological drive to eat returns to pre-treatment levels.
This is not a willpower failure. It reflects how powerfully the body defends its prior weight. Finding durable solutions for the post-GLP-1 period is one of the most pressing questions in obesity medicine right now.
What the Dartmouth Study Investigated
Researchers at Dartmouth-Hitchcock Medical Center examined whether combining GLP-1 therapy with an outpatient endoscopic procedure could produce more lasting results than medication alone.
The procedure at the center of this research is endoscopic sleeve gastroplasty, commonly called ESG. Unlike traditional bariatric surgery, ESG does not require incisions. Instead, a physician passes a flexible endoscope (a thin tube with a camera and tools) through the mouth and into the stomach, then uses sutures to fold and reduce the stomach's internal volume by roughly 70 to 80 percent.
The theory is straightforward. GLP-1 medications address the hormonal and neurological side of appetite. ESG addresses the physical capacity of the stomach. Together, they may reinforce each other. And when the medication is eventually stopped, the reduced stomach size may help patients maintain the behavioral changes and portion control they developed while on treatment.
The Dartmouth findings, while still emerging from a relatively small study population, suggest that patients who received ESG around the time of GLP-1 use maintained significantly more of their weight loss over the follow-up period compared to those who used medication alone.
What Is Endoscopic Sleeve Gastroplasty?
ESG has been available for several years as a standalone weight loss procedure and is FDA-cleared for use in adults with obesity. It's worth understanding how it compares to other options.
How ESG Works
A gastroenterologist or bariatric endoscopist performs the procedure under sedation, typically in an outpatient endoscopy suite. Using a suturing device attached to the endoscope, the physician places a series of sutures along the inside of the stomach wall, drawing the tissue together into a sleeve or tube shape. The reduced stomach volume means patients feel full faster and stay full longer.
Most patients go home the same day. Recovery typically involves a few days of a liquid diet followed by gradual reintroduction of soft and solid foods.
ESG vs. Surgical Sleeve Gastrectomy
It's important not to confuse ESG with surgical sleeve gastrectomy, which is a laparoscopic operation that permanently removes a portion of the stomach. ESG is less invasive, reversible in principle, and carries lower procedural risk. However, it also tends to produce less dramatic weight loss as a standalone treatment.
Why This Research Matters for GLP-1 Patients
Most people taking GLP-1 medications are not planning to use them forever. Cost, insurance coverage, side effects, supply issues, and personal preference all lead patients to eventually taper or stop. That's the reality.
The Dartmouth research matters because it frames ESG not just as an alternative to GLP-1 therapy but as a potential complement to it. If a structural change to the stomach can reinforce the habits and appetite recalibration achieved during GLP-1 treatment, patients may have a more durable path forward after stopping medication.
Think of it this way: GLP-1 medications help you eat less and lose weight. ESG gives your body a physical reason to continue eating less after the medication is gone.
This also raises broader questions for the field. Could other procedures, or even behavioral interventions timed strategically around medication discontinuation, produce similar effects? Researchers are beginning to take this transition period seriously as a distinct clinical challenge.
Who Might Be a Candidate for This Approach?
This combination approach is not appropriate for everyone, and it's far from standard care at this point. But certain patient profiles may make this worth a conversation with your doctor.
Potentially Good Candidates
- Adults with a BMI of 30 or higher who have already seen success on GLP-1 therapy but are planning to or need to stop due to cost, coverage, side effects, or personal preference
- Patients who have regained weight after a prior course of GLP-1 treatment and want a structural solution to prevent the same rebound pattern from repeating
- People who cannot afford or access long-term GLP-1 medication and want a physical mechanism to support weight maintenance after discontinuation
- Patients already being evaluated for bariatric procedures who want a less invasive option first, since ESG carries lower procedural risk and shorter recovery than surgical sleeve gastrectomy
Who Should Be Cautious
- People with certain gastrointestinal conditions such as large hiatal hernias, active ulcers, or prior stomach surgeries may not be suitable for ESG
- Those with eating disorders, particularly binge eating disorder, need specialized evaluation before any restrictive procedure
- Patients with bleeding disorders or those on blood thinners require careful pre-procedural assessment
Your gastroenterologist or bariatric medicine specialist is the right person to determine candidacy. No online checklist replaces that evaluation.
The Cost Question: What Patients Should Expect
Cost is a major practical consideration here, and it layers on top of what many GLP-1 patients are already managing.
GLP-1 medications like Wegovy and Mounjaro can cost $900 to $1,300 per month without insurance coverage. Many patients already feel the financial pressure. Adding an outpatient procedure that can cost $10,000 to $15,000 out of pocket is a significant ask.
Insurance Coverage for ESG
Coverage for ESG varies widely. Some private insurers cover it when specific BMI and comorbidity criteria are met, but many do not. Medicare and Medicaid coverage depends on the state and plan. Patients should call their insurer directly and ask specifically whether CPT code 43210 (the code for endoscopic sleeve gastroplasty) is covered under their plan.
If cost is a concern at the medication stage, exploring GLP-1 Coupons and manufacturer savings programs is a smart first step. Understanding total long-term costs for both the medication period and any maintenance procedures should factor into your planning.
Questions to Ask Your Doctor
Before pursuing ESG as a maintenance strategy after GLP-1 therapy, bring these specific questions to your provider:
- Am I a good candidate for ESG given my medical history and current GI health?
- What does the evidence say about combining ESG with GLP-1 therapy specifically, not just ESG as a standalone treatment?
- What is the timing? Should ESG happen before stopping medication, at the time of stopping, or after?
- What does recovery look like, and how will it affect my daily life and work?
- Does your practice have experience performing ESG specifically, and how many procedures has your team done?
- What are the realistic maintenance outcomes I should expect, and what happens if I regain weight after ESG?
- Can you help me get insurance pre-authorization, or does your office have a financial counselor who can assist?
These questions help you move from general curiosity to a real, informed conversation about whether this path makes sense for your specific situation.
No waiting list. No insurance needed.
Frequently Asked Questions
What is endoscopic sleeve gastroplasty (ESG)?
ESG is a minimally invasive outpatient procedure where a physician uses a flexible endoscope passed through the mouth to suture the inside of the stomach, reducing its volume by roughly 70 to 80 percent. No incisions are made and no stomach tissue is removed. Most patients go home the same day.
Will I regain weight when I stop taking semaglutide or tirzepatide?
Clinical data shows that most people regain a significant portion of their lost weight after stopping GLP-1 medications, often around two-thirds within a year. This happens because the drugs' appetite-suppressing hormonal effects stop when the medication is discontinued. Having a structured maintenance plan, whether through continued medication, behavioral support, or a procedure like ESG, is important.
How much does endoscopic sleeve gastroplasty cost in the U.S.?
ESG typically costs between $10,000 and $15,000 out of pocket in the United States. Insurance coverage varies significantly by plan. Patients should contact their insurer and ask specifically about coverage for CPT code 43210 before scheduling the procedure.
Is ESG covered by insurance?
Some private insurance plans cover ESG when specific BMI and health criteria are met, but many do not. Medicare and Medicaid coverage depends on individual state and plan terms. It is worth calling your insurer directly to ask about coverage, and asking your provider's office for help with pre-authorization paperwork.
How does ESG differ from bariatric surgery?
ESG does not require surgical incisions or the removal of any stomach tissue. It is performed under sedation rather than general anesthesia, recovery takes days rather than weeks, and it is potentially reversible. Bariatric surgery like sleeve gastrectomy permanently removes part of the stomach and typically produces greater weight loss, but carries higher procedural risk.
Can I get ESG while still taking a GLP-1 medication?
The Dartmouth research specifically explored the combination of GLP-1 therapy and ESG, and early findings suggest the pairing may improve long-term maintenance outcomes. The optimal timing of the procedure relative to medication use is still being studied. You should discuss the sequencing with a bariatric endoscopist or obesity medicine specialist who knows your full medical history.